Significantly, some SEV-packaged miRNAs have exhibited oncogenic activity, while others demonstrate tumor suppressive functions; for example, in head and neck cancer secreted mir-24-3p, miR-891a, miR-106a-5p, miR-2a-5p, and miR-1908 can decrease T-cell response in the tumor stroma by targeting the Mark1 signaling pathway [25] while secreted miR-21-5p can promote metastasis [26]. Here, MARK1 is linked to neoplasm.